2025 Full Year Sales Guidance Down 10% to 12% from Prior Year, and Well-Positioned to Accelerate 2026 New Program Launches COLUMBUS, Ohio, Nov. 04, 2025 (GLOBE NEWSWIRE) — Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico today reports financial and operating results for the fiscal periods ended September 30, 2025. David Duvall, the Company’s President and Chief Executive Officer, and Eric Palomaki, Chief Operating Officer, commented, “While topline challenges persist, we are enthusiastic about Core Molding’s Invest for Growth achievements, highlighted...

Business Wins and Strategic Initiatives Drove Revenue Growth While Demand Remained Stable  Higher Revenue Resulted in Gross Margin Improvement MARLBOROUGH, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) — IPG Photonics Corporation (NASDAQ: IPGP) today reported financial results for the third quarter ended September 30, 2025.    Three Months Ended September 30,       Nine Months Ended September 30,      (In millions, except per share data and percentages)     2025       2024     Change     2025       2024     Change  Revenue   $ 250.8     $ 233.1     8 %   $ 729.3     $ 742.8     (2 )%Gross margin     39.5 %     23.2 %         38.7 %     33.4 %      Operating income (loss)   $ 7.9     $ (253.3 )   NM     $ 9.8     $ (222.2 )   NM  Operating margin     3.1 %   (108.7 )%         1.3 %     (29.9 )%      Net income (loss)   $ 7.5     $ (233.6 )   NM     $ 17.8     $ (189.3 )   NM  Earnings...

Reiterates 2025 Outlook for Consolidated Revenue and Adjusted EBITDA Strengthened Balance Sheet and Extended Maturity Profile Through Recent FinancingsNet Income of $1.609 Billion for the Third Quarter Includes One-Time Gain Related to Merger with Windstream Consolidated Revenue and Adjusted EBITDA of $722.6 Million and $327.8 Million, Respectively, for the Third Quarter____________________________ LITTLE ROCK, Ark., Nov. 04, 2025 (GLOBE NEWSWIRE) — Uniti Group Inc. (“Uniti” or the “Company”) (Nasdaq: UNIT) today announced its results for the third quarter 2025. Key highlights during the quarter included:Consolidated Fiber Revenue Grew 13% Year-over-Year in the Third Quarter Kinetic Consumer Fiber Revenue Grew 26% Year-over-Year in the Third Quarter Kinetic Consumer Fiber Subscribers Grew 17% Year-over-Year in the Third Quarter Kinetic...

Generated Q3 2025 Net Revenue of $38.2 million and year-to-date revenue of $114.3 million; reaffirmed 2025 Net Revenue Guidance of $153 million – $163 million and adjusted EBITDA of $9.0 – $13.0 million ZYNRELEF® Net Revenue grew 49% in Q3 2025, as compared to Q3 2024, continuing momentum with the launch of the Vial Access Needle (VAN) and enhanced incentive program with key distributors APONVIE® Net Revenue grew 173% in Q3 2025, as compared to Q3 2024, supported by increased adoption and momentum building with the newly launched dedicated sales team in Q3 2025CARY, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) — Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three and nine months ended September 30, 2025 and recent corporate...

Third quarter net income of $17.7 millionThird quarter Adjusted EBITDA of $39.3 millionDredging backlog of $934.5 million at September 30, 2025 HOUSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) — Great Lakes Dredge & Dock Corporation (“Great Lakes” or the “Company”) (Nasdaq: GLDD), the largest provider of dredging services in the United States, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 HighlightsRevenue was $195.2 million Total operating income was $28.1 million Net income was $17.7 million Adjusted EBITDA was $39.3 million Dredging backlog as of September 30, 2025 was $934.5 millionManagement Commentary Lasse Petterson, President and Chief Executive Officer, commented, “Great Lakes delivered another solid quarter, driven by strong project execution and high equipment utilization....

FORT LEE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) — In a release issued under the same headline on November 4, 2025 at 07:30 ET by Nuvectis Pharma, Inc. (NASDAQ: NVCT), the tables were not included. The tables have been added and the corrected release follows:NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the combination portion of the program expected by year-end NXP900 Phase 1a dose escalation study successfully completed highlighting robust pharmacodynamic responses at clinically relevant doses facilitating once-daily oral dosing NXP900 clinical drug-drug interaction study in healthy volunteers successfully completed supporting our strategy for combination therapy Poster...

OTTAWA, Ontario, Nov. 04, 2025 (GLOBE NEWSWIRE) — Telesat (Nasdaq and TSX: TSAT), one of the world’s largest and most innovative satellite operators, today announced its financial results for the three and nine-month periods ended September 30, 2025. All amounts are in Canadian dollars and reported under IFRS® Accounting Standards unless otherwise noted. “I am pleased with our performance thus far in 2025,” commented Dan Goldberg, Telesat’s President and CEO. “Our Telesat Lightspeed team continues to make good progress on both the engineering and commercial fronts, as we work toward an initial satellite launch late next year and toward further expanding our $1.1 billion Telesat Lightspeed backlog. On the GEO side of the business, the year has developed largely as we had expected, and we maintain our disciplined focus on maximizing...

– Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S. Food & Drug Administration (FDA) is expected to be provided later in the fourth quarter of 2025 – – Update on Phase 1b/2 clinical trial of WTX-330 and potential further development plan is expected to be provided later in the fourth quarter of 2025 – – WTX-1011, Company’s first INDUCER™ T-cell engager development candidate targeting STEAP1, continues IND-enabling studies – WATERTOWN, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today...

– Record Quarterly Revenue of $135.8 million, an increase of 32.9% year over year – – Gross Margin of 37.0% – – Operating Profit of $18.7 million – – Adjusted EBITDA1 of $32.0 million – – Record Backlog and Awarded Orders of $720.9 million – – Provides Fourth Quarter and Full Year 2025 Revenue Outlook – PORTLAND, Tenn., Nov. 04, 2025 (GLOBE NEWSWIRE) — Shoals Technologies Group, Inc. (“Shoals” or the “Company”) (Nasdaq: SHLS), a leading provider of electrical balance of system (“EBOS”) solutions and components for the global energy transition market, today announced results for its third quarter ended September 30, 2025. “I’m very pleased with our third quarter’s performance, delivering revenue above the high-end of our guided range, record backlog and awarded orders of $720.9 million, and a book to bill of 1.4. We are executing...

Third-quarter 2025 Rezdiffra™ (resmetirom) net sales of $287.3 million As of September 30, 2025, more than 29,500 patients on Rezdiffra Closed global licensing agreement with CSPC Pharma to add oral GLP-1 to pipeline New Orange Book listed patent for Rezdiffra providing protection into 2045 Launched Rezdiffra in Germany following European Commission approval Reports cash, cash equivalents, restricted cash and marketable securities of $1.1 billion as of Sept. 30, 2025 Company to host conference call today, Nov. 4, 2025, at 8 a.m. ESTCONSHOHOCKEN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports third-quarter 2025 financial results and provides...